clinical trial · NCT07096362
Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma
University of Miami·phase2·recruiting·n = 50
Metastatic Pancreatic Ductal AdenocarcinomaPancreatic Ductal Adenocarcinoma5-FluorouracilOxaliplatinLeucovorinIrinotecanGemcitabineNab PaclitaxelCirculating Tumor Deoxyribonucleic acid (ctDNA) Assay
brief summary
The purpose of this study is to understand whether a blood-based test called circulating tumor DNA (ctDNA) can detect whether participants are having a desired tumor shrinkage or an undesired lack of tumor shrinkage, and to study whether these levels of ctDNA can be used to make treatment decisions faster than the current standard approach, which is to wait 8 weeks after starting chemotherapy to obtain participant first imaging scans since starting chemotherapy.
started
Sep 9, 2025
primary completion
Sep 30, 2030
completion
Sep 30, 2030
last updated
Sep 23, 2025
official title
A Phase 2 Study Assessing Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol